The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Aclasta     (1-hydroxy-2-imidazol-1-yl-1- phosphono...

Synonyms: Reclast, Orazol, ZOLEDRONIC, Zomera, Zometa, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of S00092

  • CONCLUSION: Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases [1].
  • Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001) [1].
  • Given its track record in clinical use with limited toxicity, ZA holds promise as an "unconventional" MMP-9 inhibitor for antiangiogenic therapy of cervical cancer and potentially for additional cancers and other diseases where MMP-9 expression by infiltrating macrophages is evident [2].
  • Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid, but there were no differences in disease progression, performance status, or quality-of-life scores among the groups [1].
  • Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone [3].

Psychiatry related information on S00092


High impact information on S00092

  • The analyses implicated cellular and molecular targets of ZA's actions: ZA suppressed MMP-9 expression by infiltrating macrophages and inhibited metalloprotease activity, reducing association of VEGF with its receptor on angiogenic endothelial cells [2].
  • ZA therapy increased neoplastic epithelial and endothelial cell apoptosis without affecting hyperproliferation, indicating that ZA was not antimitotic [2].
  • We report here high-resolution x-ray structures of the human enzyme in complexes with risedronate and zoledronate, two of the leading N-BPs in clinical use [5].
  • Likewise, osteoclast inhibition with bone-targeted zoledronic acid protected Tax+ mice from bone and soft-tissue tumors and prolonged survival [6].
  • Bisphosphonate zoledronic acid (ZOL), a RAS-blocking compound, suppressed colony formation from bone marrow (BM) cells of 8 patients with JMML and 5 healthy control subjects without and with GM-CSF (10 ng/mL), respectively, in a dose-dependent manner in clonal culture [7].

Chemical compound and disease context of S00092


Biological context of S00092


Anatomical context of S00092


Associations of S00092 with other chemical compounds


Gene context of S00092


Analytical, diagnostic and therapeutic context of S00092


  1. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goas, J.A., Chen, B. J. Natl. Cancer Inst. (2002) [Pubmed]
  2. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. Giraudo, E., Inoue, M., Hanahan, D. J. Clin. Invest. (2004) [Pubmed]
  3. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Tosi, P., Zamagni, E., Cangini, D., Tacchetti, P., Di Raimondo, F., Catalano, L., D'Arco, A., Ronconi, S., Cellini, C., Offidani, M., Perrone, G., Ceccolini, M., Brioli, A., Tura, S., Baccarani, M., Cavo, M. Blood (2006) [Pubmed]
  4. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Chapurlat, R.D. Treatments in endocrinology. (2005) [Pubmed]
  5. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Kavanagh, K.L., Guo, K., Dunford, J.E., Wu, X., Knapp, S., Ebetino, F.H., Rogers, M.J., Russell, R.G., Oppermann, U. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  6. HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Gao, L., Deng, H., Zhao, H., Hirbe, A., Harding, J., Ratner, L., Weilbaecher, K. Blood (2005) [Pubmed]
  7. RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro. Ohtsuka, Y., Manabe, A., Kawasaki, H., Hasegawa, D., Zaike, Y., Watanabe, S., Tanizawa, T., Nakahata, T., Tsuji, K. Blood (2005) [Pubmed]
  8. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Kim, S.J., Uehara, H., Yazici, S., He, J., Langley, R.R., Mathew, P., Fan, D., Fidler, I.J. Cancer Res. (2005) [Pubmed]
  9. Bisphosphonates induce breast cancer cell death in vitro. Fromigue, O., Lagneaux, L., Body, J.J. J. Bone Miner. Res. (2000) [Pubmed]
  10. Medical Management of Paget's Disease of Bone: Indications for Treatment and Review of Current Therapies. Siris, E.S., Lyles, K.W., Singer, F.R., Meunier, P.J. J. Bone Miner. Res. (2006) [Pubmed]
  11. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Thompson, K., Rogers, M.J., Coxon, F.P., Crockett, J.C. Mol. Pharmacol. (2006) [Pubmed]
  12. Bisphosphonates Inhibit the Growth of Mesothelioma Cells In vitro and In vivo. Wakchoure, S., Merrell, M.A., Aldrich, W., Millender-Swain, T., Harris, K.W., Triozzi, P., Selander, K.S. Clin. Cancer Res. (2006) [Pubmed]
  13. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Reinholz, G.G., Getz, B., Pederson, L., Sanders, E.S., Subramaniam, M., Ingle, J.N., Spelsberg, T.C. Cancer Res. (2000) [Pubmed]
  14. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Lee, M.V., Fong, E.M., Singer, F.R., Guenette, R.S. Cancer Res. (2001) [Pubmed]
  15. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. Bezzi, M., Hasmim, M., Bieler, G., Dormond, O., Rüegg, C. J. Biol. Chem. (2003) [Pubmed]
  16. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Dieli, F., Gebbia, N., Poccia, F., Caccamo, N., Montesano, C., Fulfaro, F., Arcara, C., Valerio, M.R., Meraviglia, S., Di Sano, C., Sireci, G., Salerno, A. Blood (2003) [Pubmed]
  17. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Lee, Y.P., Schwarz, E.M., Davies, M., Jo, M., Gates, J., Zhang, X., Wu, J., Lieberman, J.R. Cancer Res. (2002) [Pubmed]
  18. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. Derenne, S., Amiot, M., Barillé, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J.L., Bataille, R. J. Bone Miner. Res. (1999) [Pubmed]
  19. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Fournier, P., Boissier, S., Filleur, S., Guglielmi, J., Cabon, F., Colombel, M., Clézardin, P. Cancer Res. (2002) [Pubmed]
  20. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Caraglia, M., D'Alessandro, A.M., Marra, M., Giuberti, G., Vitale, G., Viscomi, C., Colao, A., Prete, S.D., Tagliaferri, P., Tassone, P., Budillon, A., Venuta, S., Abbruzzese, A. Oncogene (2004) [Pubmed]
  21. Treatment-related osteoporosis in men with prostate cancer. Smith, M.R. Clin. Cancer Res. (2006) [Pubmed]
  22. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Tassone, P., Forciniti, S., Galea, E., Morrone, G., Turco, M.C., Martinelli, V., Tagliaferri, P., Venuta, S. Leukemia (2000) [Pubmed]
  23. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Neville-Webbe, H.L., Rostami-Hodjegan, A., Evans, C.A., Coleman, R.E., Holen, I. Int. J. Cancer (2005) [Pubmed]
  24. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. von Knoch, F., Jaquiery, C., Kowalsky, M., Schaeren, S., Alabre, C., Martin, I., Rubash, H.E., Shanbhag, A.S. Biomaterials (2005) [Pubmed]
  25. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Tenta, R., Sourla, A., Lembessis, P., Koutsilieris, M. Anticancer Res. (2006) [Pubmed]
  26. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. Wood, J., Bonjean, K., Ruetz, S., Bellahcène, A., Devy, L., Foidart, J.M., Castronovo, V., Green, J.R. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  27. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. Breen, T.L., Shane, E. J. Clin. Oncol. (2004) [Pubmed]
  28. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Garnero, P., Gineyts, E., Schaffer, A.V., Seaman, J., Delmas, P.D. Arthritis Rheum. (1998) [Pubmed]
  29. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Sims, N.A., Green, J.R., Glatt, M., Schlict, S., Martin, T.J., Gillespie, M.T., Romas, E. Arthritis Rheum. (2004) [Pubmed]
  30. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. Croucher, P.I., De Hendrik, R., Perry, M.J., Hijzen, A., Shipman, C.M., Lippitt, J., Green, J., Van Marck, E., Van Camp, B., Vanderkerken, K. J. Bone Miner. Res. (2003) [Pubmed]
  31. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. Little, D.G., Smith, N.C., Williams, P.R., Briody, J.N., Bilston, L.E., Smith, E.J., Gardiner, E.M., Cowell, C.T. J. Bone Miner. Res. (2003) [Pubmed]
WikiGenes - Universities